Jakub Morze1,2, Anna Danielewicz3, Katarzyna Przybyłowicz3, Hongmei Zeng4,5, Georg Hoffmann6, Lukas Schwingshackl7. 1. Department of Cardiology and Internal Diseases, University of Warmia and Mazury, al. Warszawska 30, 10-082, Olsztyn, Poland. jakub.morze@uwm.edu.pl. 2. Department of Human Nutrition, University of Warmia and Mazury, ul. Sloneczna 45f, 10-718, Olsztyn, Poland. jakub.morze@uwm.edu.pl. 3. Department of Human Nutrition, University of Warmia and Mazury, ul. Sloneczna 45f, 10-718, Olsztyn, Poland. 4. National Cancer Registry Office, National Cancer Center, 17 South Lane, Beijing, 100021, China. 5. Department of Nutrition, Harvard T.H. Chan School of Public Health, 655 Huntington Ave, Building 2, Boston, MA, 02551, USA. 6. Department of Nutritional Sciences, University of Vienna, Althanstraße 14, UZA II, 1090, Vienna, Austria. 7. Institute for Evidence in Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Straße 153, 79110, Freiburg, Germany.
Abstract
PURPOSE: The aim of current systematic review was to update the body of evidence on associations between adherence to the Mediterranean diet (MedDiet) and risk of cancer mortality, site-specific cancer in the general population; all-cause, and cancer mortality as well as cancer reoccurrence among cancer survivors. METHODS: A literature search for randomized controlled trials (RCTs), case-control and cohort studies published up to April 2020 was performed using PubMed and Scopus. Study-specific risk estimates for the highest versus lowest adherence to the MedDiet category were pooled using random-effects meta-analyses. Certainty of evidence from cohort studies and RCTs was evaluated using the NutriGrade scoring system. RESULTS: The updated search revealed 44 studies not identified in the previous review. Altogether, 117 studies including 3,202,496 participants were enclosed for meta-analysis. The highest adherence to MedDiet was inversely associated with cancer mortality (RRcohort: 0.87, 95% CI 0.82, 0.92; N = 18 studies), all-cause mortality among cancer survivors (RRcohort: 0.75, 95% CI 0.66, 0.86; N = 8), breast (RRobservational: 0.94, 95% CI 0.90, 0.97; N = 23), colorectal (RRobservational: 0.83, 95% CI 0.76, 0.90; N = 17), head and neck (RRobservational: 0.56, 95% CI 0.44, 0.72; N = 9), respiratory (RRcohort: 0.84, 95% CI 0.76, 0.94; N = 5), gastric (RRobservational: 0.70, 95% CI 0.61, 0.80; N = 7), bladder (RRobservational: 0.87, 95% CI 0.76, 0.98; N = 4), and liver cancer (RRobservational: 0.64, 95% CI 0.54, 0.75; N = 4). Adhering to MedDiet did not modify risk of blood, esophageal, pancreatic and prostate cancer risk. CONCLUSION: In conclusion, our results suggest that highest adherence to the MedDiet was related to lower risk of cancer mortality in the general population, and all-cause mortality among cancer survivors as well as colorectal, head and neck, respiratory, gastric, liver and bladder cancer risks. Moderate certainty of evidence from cohort studies suggest an inverse association for cancer mortality and colorectal cancer, but most of the comparisons were rated as low or very low certainty of evidence.
PURPOSE: The aim of current systematic review was to update the body of evidence on associations between adherence to the Mediterranean diet (MedDiet) and risk of cancer mortality, site-specific cancer in the general population; all-cause, and cancer mortality as well as cancer reoccurrence among cancer survivors. METHODS: A literature search for randomized controlled trials (RCTs), case-control and cohort studies published up to April 2020 was performed using PubMed and Scopus. Study-specific risk estimates for the highest versus lowest adherence to the MedDiet category were pooled using random-effects meta-analyses. Certainty of evidence from cohort studies and RCTs was evaluated using the NutriGrade scoring system. RESULTS: The updated search revealed 44 studies not identified in the previous review. Altogether, 117 studies including 3,202,496 participants were enclosed for meta-analysis. The highest adherence to MedDiet was inversely associated with cancer mortality (RRcohort: 0.87, 95% CI 0.82, 0.92; N = 18 studies), all-cause mortality among cancer survivors (RRcohort: 0.75, 95% CI 0.66, 0.86; N = 8), breast (RRobservational: 0.94, 95% CI 0.90, 0.97; N = 23), colorectal (RRobservational: 0.83, 95% CI 0.76, 0.90; N = 17), head and neck (RRobservational: 0.56, 95% CI 0.44, 0.72; N = 9), respiratory (RRcohort: 0.84, 95% CI 0.76, 0.94; N = 5), gastric (RRobservational: 0.70, 95% CI 0.61, 0.80; N = 7), bladder (RRobservational: 0.87, 95% CI 0.76, 0.98; N = 4), and liver cancer (RRobservational: 0.64, 95% CI 0.54, 0.75; N = 4). Adhering to MedDiet did not modify risk of blood, esophageal, pancreatic and prostate cancer risk. CONCLUSION: In conclusion, our results suggest that highest adherence to the MedDiet was related to lower risk of cancer mortality in the general population, and all-cause mortality among cancer survivors as well as colorectal, head and neck, respiratory, gastric, liver and bladder cancer risks. Moderate certainty of evidence from cohort studies suggest an inverse association for cancer mortality and colorectal cancer, but most of the comparisons were rated as low or very low certainty of evidence.
Entities:
Keywords:
Cancer; Certainty of evidence; Mediterranean diet; Meta-analysis
Authors: Federica Turati; Francesca Bravi; Jerry Polesel; Cristina Bosetti; Eva Negri; Werner Garavello; Martina Taborelli; Diego Serraino; Massimo Libra; Maurizio Montella; Adriano Decarli; Monica Ferraroni; Carlo La Vecchia Journal: Cancer Causes Control Date: 2017-02-02 Impact factor: 2.506
Authors: Marta Solans; Yolanda Benavente; Marc Saez; Antonio Agudo; Sabine Naudin; Fatemeh Saberi Hosnijeh; Hwayoung Noh; Heinz Freisling; Pietro Ferrari; Caroline Besson; Yahya Mahamat-Saleh; Marie-Christine Boutron-Ruault; Tilman Kühn; Rudolf Kaaks; Heiner Boeing; Cristina Lasheras; Miguel Rodríguez-Barranco; Pilar Amiano; Jose Maria Huerta; Aurelio Barricarte; Julie A Schmidt; Paolo Vineis; Elio Riboli; Antonia Trichopoulou; Christina Bamia; Eleni Peppa; Giovanna Masala; Claudia Agnoli; Rosario Tumino; Carlotta Sacerdote; Salvatore Panico; Guri Skeie; Elisabete Weiderpass; Mats Jerkeman; Ulrika Ericson; Florentin Späth; Lena Maria Nilsson; Christina C Dahm; Kim Overvad; Anne Katrine Bolvig; Anne Tjønneland; Silvia de Sanjose; Genevieve Buckland; Roel Vermeulen; Alexandra Nieters; Delphine Casabonne Journal: Int J Cancer Date: 2019-02-05 Impact factor: 7.396
Authors: Dong Hoon Lee; Teresa T Fung; Fred K Tabung; Graham A Colditz; Irene M Ghobrial; Bernard A Rosner; Edward L Giovannucci; Brenda M Birmann Journal: JNCI Cancer Spectr Date: 2019-04-27
Authors: Song-Yi Park; Carol J Boushey; Yurii B Shvetsov; Michael D Wirth; Nitin Shivappa; James R Hébert; Christopher A Haiman; Lynne R Wilkens; Loïc Le Marchand Journal: Nutrients Date: 2021-05-12 Impact factor: 5.717